Table 3 Multivariate analysis of clinical and molecular prognosticators in adult medulloblastomas
From: Clinical and mutational profiles of adult medulloblastoma groups
| Â | HR (95% CI) | p value |
|---|---|---|
Age | 0.869 (0.755–1.002) | 0.053 |
Sex (male versus female) | 27.878 (0.382–2035.342) | 0.128 |
Molecular group | Â | 0.407 |
 SHH versus WNT | 0.894 (0.022–36.018) | 0.953 |
 Group 3 versus WNT | 5.903 (0.225–155.063) | 0.287 |
 Group 4 versus WNT | 0.306 (0.006–14.994) | 0.551 |
Histological type | Â | 0.026 |
 Desmoplastic/nodular versus classic | 0.467 (0.046–4.746) | 0.520 |
 LCA versus classic | 129.534 (2.871–5844.831) | 0.012 |
Metastasis | 7.78 (1.207–50.147) | 0.031 |
Adjuvant therapy | 0.283 (0.007–11.612) | 0.506 |
KMT2C mutation | 6.468 (1.035–40.404) | 0.046 |